Nothing Special   »   [go: up one dir, main page]

MA33489B1 - Procédé de synthèse amélioré de la pirfénidone - Google Patents

Procédé de synthèse amélioré de la pirfénidone

Info

Publication number
MA33489B1
MA33489B1 MA34508A MA34508A MA33489B1 MA 33489 B1 MA33489 B1 MA 33489B1 MA 34508 A MA34508 A MA 34508A MA 34508 A MA34508 A MA 34508A MA 33489 B1 MA33489 B1 MA 33489B1
Authority
MA
Morocco
Prior art keywords
pirfenidone
synthesis
improved process
synthesizing
butanol
Prior art date
Application number
MA34508A
Other languages
Arabic (ar)
English (en)
Inventor
Ramachadran Radhakrishnan
Mike Cyr
Sabine Marie-Francoise Brigitte Boutet
Original Assignee
Intermune Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43298478&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MA33489(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Intermune Inc filed Critical Intermune Inc
Publication of MA33489B1 publication Critical patent/MA33489B1/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D213/00—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members
    • C07D213/02—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members
    • C07D213/04—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom
    • C07D213/60—Heterocyclic compounds containing six-membered rings, not condensed with other rings, with one nitrogen atom as the only ring hetero atom and three or more double bonds between ring members or between ring members and non-ring members having three double bonds between ring members or between ring members and non-ring members having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D213/62—Oxygen or sulfur atoms
    • C07D213/63—One oxygen atom
    • C07D213/64—One oxygen atom attached in position 2 or 6
    • C07D213/643—2-Phenoxypyridines; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01N—PRESERVATION OF BODIES OF HUMANS OR ANIMALS OR PLANTS OR PARTS THEREOF; BIOCIDES, e.g. AS DISINFECTANTS, AS PESTICIDES OR AS HERBICIDES; PEST REPELLANTS OR ATTRACTANTS; PLANT GROWTH REGULATORS
    • A01N43/00—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds
    • A01N43/34—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom
    • A01N43/40—Biocides, pest repellants or attractants, or plant growth regulators containing heterocyclic compounds having rings with one nitrogen atom as the only ring hetero atom six-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4412—Non condensed pyridines; Hydrogenated derivatives thereof having oxo groups directly attached to the heterocyclic ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Rheumatology (AREA)
  • Dermatology (AREA)
  • Urology & Nephrology (AREA)
  • Pest Control & Pesticides (AREA)
  • Plant Pathology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Agronomy & Crop Science (AREA)
  • Pain & Pain Management (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Dentistry (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Environmental Sciences (AREA)
  • Cardiology (AREA)
  • Pyridine Compounds (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Agricultural Chemicals And Associated Chemicals (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Low-Molecular Organic Synthesis Reactions Using Catalysts (AREA)

Abstract

Cette invention concerne un procédé de synthèse de pirfénidone à partir d'un bromobenzène contenant moins de 0,15 % en poids environ de dibromobenzène. Des procédés de synthèse de pirfénidone sans utiliser d'acétate d'éthyle ou de n-butanol, et des procédés de synthèse de pirfénidone ayant des teneurs contrôlées d'acétate d'éthyle, de n-butanol, de di-(5-méthyl-2- pyridinone)benzènes, et autres impuretés ayant des temps de rétention spécifiés sont également décrits. Cette invention concerne également des formes pharmaceutiques formulées contenant la pirfénidone décrite.
MA34508A 2009-06-03 2010-06-02 Procédé de synthèse amélioré de la pirfénidone MA33489B1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18358809P 2009-06-03 2009-06-03
PCT/US2010/037090 WO2010141600A2 (fr) 2009-06-03 2010-06-02 Procédé de synthèse amélioré de la pirfénidone

Publications (1)

Publication Number Publication Date
MA33489B1 true MA33489B1 (fr) 2012-08-01

Family

ID=43298478

Family Applications (1)

Application Number Title Priority Date Filing Date
MA34508A MA33489B1 (fr) 2009-06-03 2010-06-02 Procédé de synthèse amélioré de la pirfénidone

Country Status (35)

Country Link
US (6) US20110003863A1 (fr)
EP (1) EP2440543B1 (fr)
JP (2) JP5848244B2 (fr)
KR (1) KR101734858B1 (fr)
CN (1) CN102482255A (fr)
AP (1) AP3630A (fr)
AR (1) AR076974A1 (fr)
AU (1) AU2010256693B2 (fr)
BR (1) BRPI1011015B8 (fr)
CA (1) CA2764043C (fr)
CL (1) CL2011003069A1 (fr)
DK (1) DK2440543T3 (fr)
EA (1) EA021826B1 (fr)
ES (1) ES2538103T3 (fr)
GE (1) GEP20156223B (fr)
HN (1) HN2011003187A (fr)
HR (1) HRP20150696T1 (fr)
HU (1) HUE026014T2 (fr)
IL (1) IL216565A (fr)
MA (1) MA33489B1 (fr)
MX (1) MX2011012654A (fr)
MY (1) MY162443A (fr)
NI (1) NI201100211A (fr)
NZ (1) NZ596872A (fr)
PE (1) PE20120398A1 (fr)
PL (1) PL2440543T3 (fr)
PT (1) PT2440543E (fr)
RS (1) RS54031B1 (fr)
SG (1) SG176648A1 (fr)
SI (1) SI2440543T1 (fr)
TN (1) TN2011000615A1 (fr)
TW (1) TWI434833B (fr)
UA (1) UA106759C2 (fr)
WO (1) WO2010141600A2 (fr)
ZA (1) ZA201108794B (fr)

Families Citing this family (26)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN102099036B (zh) 2008-06-03 2015-05-27 英特芒尼公司 用于治疗炎性疾患和纤维化疾患的化合物和方法
US10105356B2 (en) 2011-01-31 2018-10-23 Avalyn Pharma Inc. Aerosol pirfenidone and pyridone analog compounds and uses thereof
HUE058753T2 (hu) 2011-01-31 2022-09-28 Avalyn Pharma Inc Aeroszol formájú pirfenidon- és piridon-analóg vegyületek és alkalmazásaik
MX2011007675A (es) 2011-07-19 2012-07-11 Cell Therapy And Technology S A De C V Procedimiento para la fabricacion de una composicion farmaceutica en forma de tabletas de liberacion prolongada conteniendo pirfenidona y su aplicacion en la regresion de la insuficiencia renal cronica, contractura capsular mamaria y fibrosis hepatica humanas.
MX356551B (es) 2012-08-23 2018-06-04 Grupo Medifarma S A De C V Star Composición antiséptica, antiseborreica y exfoliante para eliminar o prevenir el acné.
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
NZ760541A (en) 2014-01-10 2022-08-26 Avalyn Pharma Inc Aerosol pirfenidone and pyridone analog compounds and uses thereof
KR102373700B1 (ko) 2014-04-02 2022-03-11 인터뮨, 인크. 항섬유성 피리디논
JP2017527611A (ja) * 2014-08-15 2017-09-21 ピクサーバイオ コーポレーション 脊髄損傷を有する患者において炎症を阻害するための組成物、及びそれを使用する方法
EP3307714A1 (fr) * 2015-01-26 2018-04-18 Ulkar Kimya Sanayii Ve Ticaret A. S. Procédé amélioré de synthèse et de purification de pirfénidone
ITUB20154832A1 (it) * 2015-10-29 2017-04-29 Procos Spa Processo per la sintesi di pirfenidone
CN105315198A (zh) * 2015-11-02 2016-02-10 重庆康乐制药有限公司 一种吡非尼酮的晶型及其制备方法
CN105330598B (zh) * 2015-12-02 2017-11-14 新发药业有限公司 一种吡非尼酮的制备方法
WO2017122139A1 (fr) * 2016-01-14 2017-07-20 Laurus Labs Limited Procédé perfectionné de préparation de pirfénidone
US11066368B2 (en) 2016-01-14 2021-07-20 Laurus Labs Limited Process for the preparation and particle size reduction of pirfenidone
WO2017130166A1 (fr) * 2016-01-31 2017-08-03 Granules India Limited Procédé amélioré pour la préparation de médicament anti-fibrotique de haute pureté
CA2937365C (fr) 2016-03-29 2018-09-18 F. Hoffmann-La Roche Ag Formulation en granules de 5-methyl-1-phenyl-2-(1h)-pyridone et methode de fabrication associee
US20180009753A1 (en) * 2016-07-08 2018-01-11 Dipharma Francis S.R.L. Method for preparing an antifibrotic agent
IT201600108927A1 (it) * 2016-10-27 2018-04-27 Dipharma Francis Srl Metodo per sintetizzare un farmaco antifibrotico
IT201600071672A1 (it) * 2016-07-08 2018-01-08 Dipharma Francis Srl Metodo per sintetizzare un farmaco immunosoppressore
WO2018083709A1 (fr) * 2016-11-07 2018-05-11 Msn Laboratories Private Limited, R&D Center Procédé amélioré pour la préparation de 5-méthyl-1-phényl-2-1 (h)-pyridone pure
WO2018178996A1 (fr) * 2017-03-28 2018-10-04 Natco Pharma Limited Procédé amélioré pour la préparation de pirfénidone
CA3108048A1 (fr) 2017-07-31 2019-02-07 Washington University Derives de la pirfenidone pour la modulation de l'activite des lymphocytes b et la protection des organes
ES2886152T3 (es) 2017-12-11 2021-12-16 Laurus Labs Ltd Un procedimiento mejorado para la preparación de pirfenidona
CN112409246B (zh) * 2019-08-21 2023-04-07 北京凯因科技股份有限公司 一种吡非尼酮的晶型及其制备方法
US20230158004A1 (en) * 2020-04-22 2023-05-25 Yungjin Pharm. Co., Ltd. Enteric-coated preparation comprising pirfenidone having improved safety and stability, and method for preparing same

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3839346A (en) * 1972-12-18 1974-10-01 Affiliated Med Res N-substituted pyridone and general method for preparing pyridones
CA2099868C (fr) * 1991-01-31 2002-04-02 Thomas Richard Belliotti 4,6-di-tert-butyl-5-hydroxy-pyrimidines substituees
JPWO2002085858A1 (ja) * 2001-04-20 2004-08-12 旭硝子株式会社 精製されたピペリジン誘導体の製造方法
KR100898888B1 (ko) * 2001-08-06 2009-05-21 시오노기세이야쿠가부시키가이샤 5-메틸-1-페닐-2(1ｈ)피리디논의 제조 방법
CN1218942C (zh) 2002-06-11 2005-09-14 中南大学湘雅医学院 抗纤维化吡啶酮化合物及其生产工艺方法
CN100396669C (zh) * 2006-03-15 2008-06-25 浙江省医学科学院 一种抗纤维化药物吡非尼酮的制备方法
MX2007006349A (es) 2007-05-29 2009-02-18 Cell Therapy And Technology S Nuevo proceso de sintesis para la obtencion de 5-metil-1-fenil-2-(ih)-piridona, composicion y uso de la misma.
CN101842355A (zh) * 2007-06-20 2010-09-22 奥斯拜客斯制药有限公司 作为纤维化抑制剂的取代的n-芳基吡啶酮
US20090131485A1 (en) * 2007-09-10 2009-05-21 Concert Pharmaceuticals, Inc. Deuterated pirfenidone

Also Published As

Publication number Publication date
CA2764043A1 (fr) 2010-12-09
ES2538103T3 (es) 2015-06-17
TWI434833B (zh) 2014-04-21
SG176648A1 (en) 2012-01-30
EA201101695A1 (ru) 2012-05-30
IL216565A (en) 2015-06-30
ZA201108794B (en) 2013-03-27
UA106759C2 (uk) 2014-10-10
AU2010256693B2 (en) 2015-09-17
US20150368200A1 (en) 2015-12-24
GEP20156223B (en) 2015-01-26
TW201043602A (en) 2010-12-16
TN2011000615A1 (en) 2013-05-24
NI201100211A (es) 2012-08-01
IL216565A0 (en) 2012-03-01
AP3630A (en) 2016-03-08
RS54031B1 (en) 2015-10-30
AU2010256693A1 (en) 2012-01-12
CA2764043C (fr) 2018-01-16
PE20120398A1 (es) 2012-05-13
AR076974A1 (es) 2011-07-20
KR20120016277A (ko) 2012-02-23
JP2012528877A (ja) 2012-11-15
MX2011012654A (es) 2012-01-12
PT2440543E (pt) 2015-07-03
BRPI1011015B8 (pt) 2021-05-25
CN102482255A (zh) 2012-05-30
JP2016026196A (ja) 2016-02-12
WO2010141600A3 (fr) 2011-04-21
CL2011003069A1 (es) 2012-05-25
SI2440543T1 (sl) 2015-06-30
EA021826B1 (ru) 2015-09-30
BRPI1011015B1 (pt) 2020-11-10
US20120016133A1 (en) 2012-01-19
MY162443A (en) 2017-06-15
HRP20150696T1 (hr) 2015-08-28
DK2440543T3 (en) 2015-05-18
PL2440543T3 (pl) 2015-09-30
AP2012006052A0 (en) 2012-02-29
US20140221660A1 (en) 2014-08-07
EP2440543A4 (fr) 2012-11-21
HN2011003187A (es) 2015-02-02
US20130345430A1 (en) 2013-12-26
BRPI1011015A2 (pt) 2018-02-14
EP2440543A2 (fr) 2012-04-18
US20150065720A1 (en) 2015-03-05
NZ596872A (en) 2013-12-20
US20110003863A1 (en) 2011-01-06
JP5848244B2 (ja) 2016-01-27
WO2010141600A2 (fr) 2010-12-09
EP2440543B1 (fr) 2015-04-15
HUE026014T2 (en) 2016-05-30
US8519140B2 (en) 2013-08-27
KR101734858B1 (ko) 2017-05-12

Similar Documents

Publication Publication Date Title
MA33489B1 (fr) Procédé de synthèse amélioré de la pirfénidone
TW200736258A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
WO2009012109A3 (fr) Composes contenant de la cyanine utiles dans l'imagerie et le traitement du cancer
HK1139658A1 (en) Benzimidazole derivatives
TW200607801A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
NO20063518L (no) Ny krystallinsk form IV av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063516L (no) Ny krystallinsk form III av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
NO20063517L (no) Ny krystallinsk form v av agomelatin, fremgangsmate for dens fremstilling og farmasoytiske sammensetninger inneholdende den
TW200716652A (en) Thienotriazolodiazepine compound and a medicinal use thereof
TW200612949A (en) Pyrimidine derivatives for the treatment of abnormal cell growth
CL2007002080A1 (es) Compuestos derivados de piridazina; su proceso de preparación; composición fungicida para controlar o proteger contra microorganismos fitopatogénicos; uso de dichos compuestos; metodo para controlar o prevenir la infestación de cultivos o materiales inertes; y proceso de preparación de compuestos intermediarios.
TNSN07383A1 (en) 1-h-quinazoline-2,4-diones and their use as ampa-receptor ligands
WO2007076085A3 (fr) Pyrimidones et thiopyrimidones fusionnees et leurs utilisations
Cirés et al. Temperature-dependent dispersal strategies of Aphanizomenon ovalisporum (Nostocales, Cyanobacteria): implications for the annual life cycle
UA99447C2 (ru) Способ получения силденафила
UA110128C2 (uk) Індолкарбоксаміди та бензімідазолкарбоксаміди як інсектициди та акарициди
WO2008140641A3 (fr) Palipéridone pure et ses procédés de préparation
TW200612964A (en) Methods for preparing p2x7 inhibitors
ZA201006655B (en) Plant disease controlling composition and method for controlling plant disease
WO2008106125A3 (fr) Antagonistes du récepteur alpha 1a-adrénergique
IL183104A0 (en) Method for production of candesartan
ES2333026T3 (es) Derivados de ciclohexil-1,4-diamina sustituidos.
WO2007147480A3 (fr) Formes polymorphes et procédé
UA93313C2 (en) Benzimidazole derivatives
DE50310168D1 (de) Polyisoprenyl-benzophenon-derivate, verfahren zu ihrer herstellung und verwendung derselben